Mirabella Financial Services LLP Has $2.41 Million Position in AbbVie Inc. $ABBV

Mirabella Financial Services LLP reduced its stake in AbbVie Inc. by 69.5% in Q2, owning 12,919 shares worth $2.41 million. Other institutional investors adjusted their positions in AbbVie. Analysts have varied ratings, with a consensus of "Moderate Buy" and a target price of $241.85. AbbVie reported Q3 earnings of $1.86 EPS, beating estimates, and increased its dividend to $1.73 per share. The stock opened at $228.68, with a market cap of $404.17 billion.

Mirabella Financial Services LLP cut its holdings in AbbVie Inc. (NYSE:ABBV - Free Report) by 69.5% in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 12,919 shares of the company's stock after selling 29,471 shares during the quarter. Mirabella Financial Services LLP's holdings in AbbVie were worth $2,409,000 as of its most recent SEC filing.

HIMS Has Been a Roller Coaster Ride. Should Investors Hop On?

A number of other institutional investors have also recently bought and sold shares of the stock. TD Capital Management LLC lifted its position in AbbVie by 82.9% in the 1st quarter. TD Capital Management LLC now owns 128 shares of the company's stock valued at $27,000 after acquiring an additional 58 shares in the last quarter. Marshall & Sullivan Inc. WA bought a new stake in shares of AbbVie in the second quarter valued at about $25,000. Spurstone Advisory Services LLC acquired a new position in shares of AbbVie during the second quarter worth about $28,000. Financial Gravity Companies Inc. bought a new position in shares of AbbVie during the second quarter worth about $36,000. Finally, Bear Mountain Capital Inc. raised its position in AbbVie by 480.6% in the 2nd quarter. Bear Mountain Capital Inc. now owns 209 shares of the company's stock valued at $40,000 after buying an additional 173 shares during the last quarter. Institutional investors own 70.23% of the company's stock.

Wall Street Analysts Forecast Growth

ABBV has been the topic of a number of recent research reports. Daiwa America upgraded shares of AbbVie from a "hold" rating to a "strong-buy" rating in a report on Thursday, August 7th. Cantor Fitzgerald set a $250.00 price target on shares of AbbVie and gave the stock an "overweight" rating in a research report on Thursday, October 9th. UBS Group raised their price objective on AbbVie from $195.00 to $220.00 and gave the company a "neutral" rating in a report on Friday, November 7th. Evercore ISI increased their price target on AbbVie from $207.00 to $222.00 and gave the company an "outperform" rating in a research report on Monday, September 22nd. Finally, Guggenheim upped their price objective on AbbVie from $227.00 to $242.00 and gave the stock a "buy" rating in a research note on Monday, October 20th. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and ten have given a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $241.85.

Healthcare Rotation Underway: 3 Stocks Leading the Charge

Check Out Our Latest Research Report on AbbVie

AbbVie Trading Down 0.7%

ABBV stock opened at $228.68 on Friday. AbbVie Inc. has a one year low of $164.39 and a one year high of $244.81. The stock has a market cap of $404.17 billion, a price-to-earnings ratio of 173.24, a price-to-earnings-growth ratio of 1.24 and a beta of 0.36. The company has a fifty day moving average price of $228.19 and a two-hundred day moving average price of $207.90. The company has a debt-to-equity ratio of 44.14, a current ratio of 0.72 and a quick ratio of 0.60.

ABBV Stock: $250 May Be the New Floor After Big Q3 Earnings Beat

AbbVie (NYSE:ABBV - Get Free Report) last announced its earnings results on Friday, October 31st. The company reported $1.86 EPS for the quarter, topping the consensus estimate of $1.77 by $0.09. The business had revenue of $15.78 billion during the quarter, compared to the consensus estimate of $15.58 billion. AbbVie had a net margin of 4.00% and a return on equity of 3,216.47%. AbbVie's revenue was up 9.1% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $3.00 EPS. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. Equities analysts anticipate that AbbVie Inc. will post 12.31 EPS for the current year.

AbbVie Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, February 17th. Stockholders of record on Friday, January 16th will be issued a dividend of $1.73 per share. This is an increase from AbbVie's previous quarterly dividend of $1.64. This represents a $6.92 dividend on an annualized basis and a dividend yield of 3.0%. The ex-dividend date of this dividend is Friday, January 16th. AbbVie's payout ratio is 496.97%.

AbbVie Profile

(Free Report)

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.

Should You Invest $1,000 in AbbVie Right Now?

Before you consider AbbVie, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AbbVie wasn't on the list.

While AbbVie currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here